Literature DB >> 6094642

Zoster in the elderly: clinical, immunologic and therapeutic considerations.

J P Harnisch.   

Abstract

Herpes zoster is common in the elderly. Persons over the age of 50 years have an attack rate double that of patients less than 50 years old. In the very aged, this rate nearly doubles again. The loss of cell-mediated immunity for the VZ virus appears to be the primary factor in the disruption of the dynamic containment process responsible for VZ virus latency within the sensory ganglion. Humoral immunity may play a role in the maintenance of latency, but the degree is unproven, except in the case of dissemination where loss of detectable antibodies seems to correlate with extradermatomal dissemination. Severe forms of the disease and its complications, e.g., postherpetic neuralgia, are likely among the elderly. Direct immunofluorescent staining or cytologic examination is useful for early diagnosis, and serologic changes can document the confusing clinical entity of zoster sine herpete.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094642     DOI: 10.1111/j.1532-5415.1984.tb06298.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  16 in total

1.  Presentation and management of herpes zoster (shingles) in the geriatric population.

Authors:  Kenneth R Cohen; Rebecca L Salbu; Jerry Frank; Igor Israel
Journal:  P T       Date:  2013-04

2.  Lymphocyte responses to varicella zoster virus in the elderly.

Authors:  A R Hayward; M Herberger
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

3.  Efficacy of varicella (VZV) vaccination: an update for the clinician.

Authors:  Lili Wang; Lucy Zhu; Hua Zhu
Journal:  Ther Adv Vaccines       Date:  2016-01-01

4.  T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV.

Authors:  A R Hayward
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Varicella zoster virus latency.

Authors:  Emily Eshleman; Aamir Shahzad; Randall J Cohrs
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

Review 6.  Varicella zoster virus vaccines: potential complications and possible improvements.

Authors:  Benjamin Silver; Hua Zhu
Journal:  Virol Sin       Date:  2014-10-24       Impact factor: 4.327

7.  Severe herpes zoster infection in the United Kingdom: experience in a regional infectious disease unit.

Authors:  P Bannister; B Crosse
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

8.  Clinical and molecular aspects of varicella zoster virus infection.

Authors:  Don Gilden; Maria A Nagel; Ravi Mahalingam; Niklaus H Mueller; Elizabeth A Brazeau; Subbiah Pugazhenthi; Randall J Cohrs
Journal:  Future Neurol       Date:  2009-01-01

9.  Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures.

Authors:  Y Zhang; M Cosyns; M J Levin; A R Hayward
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

Review 10.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.